Drugs with Medicare negotiated prices in 2027
| Drug | Commonly used for | Negotiated price since |
|---|---|---|
| Ozempic, Rybelsus, Wegovy | type 2 diabetes; heart disease with diabetes or with obesity or overweight | 2027 |
| Trelegy Ellipta, Breo Ellipta | asthma, COPD | 2027 |
| Otezla, Otezla XR | plaque psoriasis, psoriatic arthritis, Behçet's mouth ulcers | 2027 |
| Janumet, Janumet XR; Tradjenta | type 2 diabetes | 2027 |
| Xtandi, Ibrance, Calquence, Pomalyst | cancers (see cancer pills) | 2027 |
| Ofev | idiopathic pulmonary fibrosis | 2027 |
| Linzess; Xifaxan | chronic constipation and IBS; hepatic encephalopathy | 2027 |
| Austedo, Austedo XR; Vraylar | movement disorders; bipolar disorder, depression, schizophrenia | 2027 |
| Eliquis | atrial fibrillation, blood clots | 2026 |
| Jardiance, Farxiga | type 2 diabetes, heart failure, kidney disease | 2026 |
| Januvia | type 2 diabetes | 2026 |
| Enbrel | rheumatoid arthritis, psoriasis | 2026 |
| Imbruvica | blood cancers | 2026 |
CMS posts each negotiated price on its "Selected drugs and negotiated prices" page. They aren't repeated here, because your plan, not the negotiated price, sets what you pay.
Drugs that lose their negotiated price on January 1, 2027
A drug leaves the program once a generic or biosimilar version is approved and marketed. CMS made that determination for four first-round drugs, effective January 1, 2027:
- Stelara
- Xarelto
- Entresto
- NovoLog and Fiasp insulins (the $35 monthly cap on covered insulin still applies; see insulin)
If you take one, read your plan's 2027 Annual Notice of Change.
Drugs selected for 2028
On January 27, 2026, CMS selected 15 drugs for prices starting January 1, 2028, including Trulicity, Biktarvy, Entyvio, Botox and the cancer pills Erleada, Kisqali, Verzenio and Lenvima. Some are paid under Part B, a first for the program.
What it means for you in Nevada
- Check the formulary, not the price list. A negotiated price doesn't mean any of Nevada's 9 standalone Part D plans for 2027, or your Medicare Advantage plan, covers the drug. Look up your drugs on PlanMatch or Medicare.gov's Plan Finder.
- Remember the yearly cap. Whatever the price, your 2027 out-of-pocket spending on covered Part D drugs stops at $2,400.
- Weight loss is still excluded. Semaglutide's negotiated price doesn't let Part D plans cover Wegovy for weight loss alone; CMS's separate Medicare GLP-1 Bridge covers it for eligible people through 2027.
- If your plan is ending, pick new drug coverage by December 31, 2026, to avoid a gap. See plans ending in 2027 and What if my Medicare Advantage plan is ending?
- Compare before December 7, 2026. You can request a call from a licensed insurance agent, who can compare plans from the companies they work with.
Nevada's Senior Rx program ended on December 31, 2023, so federal Extra Help is the main help with drug costs. All 25 drug pages: Medicare drug coverage in Nevada.
Related questions
Sources
- CMS — Selected drugs and negotiated prices (2026 and 2027 lists and removals; updated November 2, 2026)
- CMS — Negotiated prices for initial price applicability year 2027 (fact sheet)
- CMS — Selected drugs for initial price applicability year 2028 (January 27, 2026)
- CMS — Medicare GLP-1 Bridge (July 1, 2026, to December 31, 2027)
- CMS — CY 2027 Rate Announcement (2027 Part D cap, deductible and Extra Help copays)
- CMS — Medicare Advantage and Part D Landscape files, 2027 (PDP Region 29: Nevada)
Part of the guide: Medicare drug coverage in Nevada: 25 drugs, plain English · All questions
Frequently asked questions
Does a negotiated price mean my copay goes down?
Not necessarily. The negotiated price (the law calls it a maximum fair price) is what Part D plans and pharmacies pay. Your copay or coinsurance is set by your plan, so check its 2027 formulary.
Does a negotiated price mean every Nevada plan covers the drug?
No. Each of Nevada's 9 standalone Part D plans for 2027, and each Medicare Advantage plan with drug coverage, decides its own formulary. Look up the drug on each plan you're comparing.
Which drugs are next?
On January 27, 2026, CMS selected 15 drugs for prices starting in 2028, including Trulicity, Biktarvy, Entyvio and Botox, and for the first time included drugs paid under Part B. It also chose Tradjenta for renegotiation.
Medicare in your Nevada county
Plans, local agents and help, county by county: Clark · Washoe · Lyon · Carson City · Nye · Elko · Douglas · Churchill · Humboldt · White Pine · Pershing · Lander · Mineral · Lincoln · Storey · Eureka · Esmeralda · All 17 counties →